Archive for the ‘Conference Coverage with Social Media’ Category

2017 Agenda – BioInformatics: Track 6: BioIT World Conference & Expo ’17, May 23-35, 2017, Seaport World Trade Center, Boston, MA

Reporter: Aviva Lev-Ari, PhD, RN






7:00 am Workshop Registration and Morning Coffee

8:0011:30 Recommended Morning Pre-Conference Workshops*

(W4) Data Visualization to Accelerate Biological Discovery

12:304:00 pm Recommended Afternoon Pre-Conference Workshops*

(W13) Proteogenomics: Integration of Genomics and Proteomics Data

* Separate registration required.

2:006:00 Main Conference Registration Open


Click here for detailed information

5:007:00 Welcome Reception in the Exhibit Hall with Poster Viewing


7:00 am Registration Open and Morning Coffee


Click here for detailed information

9:50 Coffee Break in the Exhibit Hall with Poster Viewing


10:50 Chairperson’s Remarks

Kevin Merlo, BioSafety Development Engineer, Dassault Systemes

11:00 Innovative Data Integration Applicable for Therapeutic Protein Development 2.0

Wolfgang Paul, Group Leader and Senior Scientist, Large Molecule Research, Roche

Therapeutic proteins are registered including sequence, structural and functional data and information. Millions of data points are captured during the development of Roche’s innovative therapeutic proteins in data warehouse used by DAMAS (data acquisition, management and analyses system). Fast access and visualization of relevant process and analytical data drive scientific discussion and decision making. Analyzing the stored big data is key towards process development of therapeutic proteins 2.0.

11:30 Informatics – A Silver Bullet for Pharmaceutical Sciences?

William Loging, Ph.D., Associate Professor of Genomics & Head, Production Bioinformatics, Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai

The Pharmaceutical Sciences field is in constant search for the next big innovative push that will increase the success rate of drug programs. The fields of computational chemistry, structural bioinformatics – just to name a few – have changed the way drug researchers look for and identify novel drug candidates. Utilizing more than 15 years of Pharmaceutical experience, and using real world examples of high provide drug projects, this talk will provide practical steps for the merger of informatics and the strategic approaches needed for drug discovery success.

12:00 pm Big Data-Driven Bioinformatics

Frank Lee, Ph.D., Healthcare Life Sciences Industry Leader, Software Defined Infrastructure, IBM Systems, IBM

IBM will discuss the IBM Reference Architecture for Genomics, its new features, and case studies: hybrid cloud with integrated workload and data management for high performance genomics analytics; container technologies for migrating and sharing application and data; and application portal and metadata engine for global access to and searching of distributed resources. A demo of a hybrid cloud-based bioinformatics solution will follow.

12:30 Session Break

12:40 Luncheon Presentation I to be Announced

1:10 Luncheon Presentation II to be Announced

1:40 Session Break


1:50 Chairperson’s Remarks

1:55 PANEL DISCUSSION: Linking and Finding Information Using the IUPAC InChI Standard for Chemical Structures

Steve Heller, Ph.D., Project Director, InChI Trust; Scientific Information Consultant (Moderator)

Evan Bolton, Ph.D., Lead Scientist, National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), and National Institutes of Health (NIH)

Keith T. Taylor, BSc, Ph.D., MRSC, Principal, Ladera Consultancy

Tyler Peryea, Informatics Scientist, National Center for Advancing Translational Sciences (NCATS)

Lawrence Callahan, Ph.D., Chemist, Substance Registration System, Office of Critical Path Programs, Food and Drug Administration (FDA)

This session will highlight on-going efforts to strengthen and expand the non-proprietary IUPAC International Chemical Identifier (InChI) standard for chemical structures and its hashed-form, the InChIKey. Information standards are critical to enable effective communication of scientific content. Funding to maintain InChI comes from most major publishers and database providers as well as governmental agencies (NIH, FDA and NIST). The InChI is an open-source, widely adopted standard found in most chemical information containing databases, including those from Chemical Abstracts, Reaxys, ChEMBL, OpenPHACTS, PubChem, DrugBank, PDB, Sigma-Aldrich, and many others, such as internal Pharma corporate databases. InChI is an addition to a database, not a replacement. With the implementation of the ISO identification of medicinal products (IDMP) and the related ISO 11238 standards, adding and having an InChI will allow for an easier, effective, and more complete search for information on a particular drug.

2:55 Sponsored Presentation (Opportunity Available)

3:10 Integrated Informatics for Biologics Discovery

Robert Brown, Ph.D., Vice President, Product Marketing, Dotmatics

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing


4:00 Building Disease Networks Using Text Mining and Machine Learning Techniques

Kamal Rawal, Ph.D., Assistant Professor, Biotech and Bioinformatics, Jaypee Institute of Information Technology

Obesity is a global epidemic affecting over 1.5 billion people and is one of the risk factors for several diseases such as type 2 diabetes mellitus and hypertension. We have constructed a comprehensive map of the molecules reported to be implicated in obesity. Using text mining & deep curation strategies combined with omics data, we have explained the therapeutics and side effects of several drugs (i.e., orlistat) at network level.

4:20 Big Data and Systems Biology: From Genome to Phenome (and Everything in Between)

Dan Jacobson, Ph.D., Computational Biologist, Oak Ridge National Laboratory

4:40 Novel Feature Selection Strategies for Enhanced Predictive Modeling and Deep Learning in the Biosciences

Tom Chittenden, Ph.D., D.Phil., Lecturer and Senior Biostatistics and Mathematical Biology Consultant, Harvard Medical School

We have built a robust AI approach that precisely assesses pathogenicity for all genomic missense variants. Coupled with our advanced deepCODE mathematical statistics feature selection strategy for constructing deep learning models, we are able to quantitatively integrate a priori pathway-based biological knowledge with multiple types of high-throughput omics data.

5:00 Network Analysis for Drug Discovery: Benchmarking Results and Best Practices Reported by CBDD Consortium

Marina Bessarabova, Ph.D., Senior Director, Discovery and Translational Science, Life Sciences Professional Services, Clarivate Analytics (Formerly the IP & Science Business of Thomson Reuters)

A large number of advanced approaches to network analysis of -omics data were developed by academia groups in the past 15 years. Adoption of these approaches in drug development requires thorough review of the published approaches, implementation of methods identified as potentially applicable to drug development and benchmarking of the methods with an aim to establish best practices for application of the methods to diseases and mechanism of action understanding, target identification, drug repositioning, patient stratification, biomarker discovery, and drug combination effect prediction. CBDD (Computational Biology Methods for Drug Discovery) is a precompetitive consortium between Novartis, Pfizer, Sanofi, Janssen, Regeneron, UCB, Roche, Takeda, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Merck and Clarivate Analytics (formally Thomson Reuters) focused on adoption of network analysis approaches in drug development: literature review, method implementation and benchmarking. Benchmarking results and best practices for application of network analysis in drug development established by members of the program will be shared during the presentation.

5:30 15th Anniversary Celebration in the Exhibit Hall with Poster Viewing and Best of Show Awards


7:00 am Registration Open and Morning Coffee


8:05 Benjamin Franklin Awards and Laureate Presentation

8:35 Best Practices Awards Program

8:50 Plenary Keynote

Click here for detailed information

9:45 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced


10:30 Chairperson’s Remarks

Bino John, Ph.D., Computational Biology Group Leader, Dow AgroSciences LLC

10:40 How Biotech and Big Data Are Changing Agro Industry

Bino John, Ph.D., Computational Biology Group Leader, Dow AgroSciences LLC

More than 70% of the increase in food production in the next 50 years is expected to come from technological advances. Indeed, recent advances in genomics and phenomics are beginning to transform the Agro-industry, whereby creating new opportunities for informatics disciplines. While informatics needs in managing, analyzing, and visualizing big data share commonalties between Agro and the biomedical communities, Agro companies face unprecedented challenges in big biological data, generally larger than their peers in the biomedical community.

11:00 Offering Outcomes: How Digital Farming Data Is Enabling New Business Models

Tobias Menne, Global Head of Digital Farming, Bayer

11:20 Building the Next-Generation R&D IT Infrastructure for Small Molecule Discovery

Paimun Amini, Chemistry IT Lead, R&D IT, Monsanto Company

Barrett Foat, Ph.D., Data Science Team Lead, Agricultural Productivity Innovations, Monsanto

The Pharma boom in the 90s & 2000s led to the emergence of a rich ecosystem of software companies focused on delivering the IT needs for small molecule discovery. Today, cloud data storage, IoT, and the growth of predictive analytics present new opportunities for the evolution of the R&D pipeline. New technologies allow for integrated software and hardware solutions that optimize productivity while removing the risk of technical debt.

11:40 Sponsored Presentation (Opportunity Available)

12:10 pm Session Break

12:20 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Dessert Refreshment Break in the Exhibit Hall with Poster Viewing


1:55 Chairperson’s Remarks

Michael N. Liebman, Ph.D., Managing Director, IPQ Analytics, LLC and Strategic Medicine, Inc.

2:00 Distinguishing between Precision Medicine and Accurate Medicine: Application to Heart Failure Patients and Clinical Practice

Michael N. Liebman, Ph.D., IPQ Analytics, LLC and Strategic Medicine, Inc.

Increasingly, patient stratification based on genomic analysis is being considered in disease management. Critically, the need to understand real world medical practice and real world patient complexities extends far beyond the genome of the patient. We have shown examples of this complexity in heart disease and how this impacts development of clinical guidelines, trial design, and development of new patient management approaches.

2:30 CARPEDIEM – Comorbidity and Risk Profiles Evaluation in Diabetes and Heart Morbidities

Sabrina Molinaro, Psy.D., Ph.D., Head, Department of Epidemiology and Health Services, Institute of Clinical Physiology, National Research Council of Italy

Our project uniquely develops a patient record that includes clinical and individual factors (EHR-driven phenotyping) that will be validated through the comparison of existing standards for building new risk algorithms. An understanding of the current limitations and biases of risk profiling in heart disease and diabetes and how an extended, integrated database and automatic rule-based classification system can be used to improve patient management.

3:00 PANEL DISCUSSION: Precision Medicine vs. Accurate Medicine: The Need to Understand Real World Medicine and Real World Patients

Michael N. Liebman, Ph.D., IPQ Analytics, LLC and Strategic Medicine, Inc. (Moderator)

Charles Barr, M.D., MPH, Group Medical Director and Head, Evidence Science and Innovation, Genentech

Hal Wolf, Director, National Leader of Information and Digital Health Strategy, The Chartis Group

4:00 Conference Adjourns




Read Full Post »

The 35th Annual J.P. Morgan Healthcare Conference, January 9, 2017 to January 13, 2017, Westin St. Francis Hotel, San Francisco

Reporter: Aviva Lev-Ari, PhD, RN


BioPharm Insight Exclusive Event


Panel Discussion 5:30 – 6:30 PM 
Immuno-Oncology: Filtering the hype for the next wave of targets

Panel discussion as key opinion leaders (KOLs) and industry experts take on the tough questions in the field. Topics to be discussed include next-generation I/O therapeutics, pricing and reimbursement expectations, and more.

Axel Hoos, MD, PhD, SVP Oncology R&D, GSK
Ira Mellman, PhD, VP Cancer Immunology, Genentech
Lindee Goh, Partner, Tapestry Networks
Omid Hamid, MD, Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic
Ramy Ibrahim, MD, VP and Head of R&D, Parker Institute for Cancer Immunotherapy
Moderated by Querida Anderson, Editor in Chief at BioPharm Insight

*This panel is brought to you by BioPharm Insight and The Immuno-Oncology 360° team at The Conference Forum

Networking Reception 6:30 – 8:30 PM

You’re invited to join us for a networking reception following the panel discussion. We know how busy this week is, so feel free to pop-in after the panel for cocktails and light fare. Mix and mingle with the BioPharm Insight team, industry experts and fellow peers.

JANUARY 9, 2017

Chandran Art Gallery

459 Geary St

San Francisco, CA




Read Full Post »

11th annual BioPharma & Healthcare Summit, USA-India Chamber of Commerce, May 18, 2017 @ Marriott Cambridge, Massachusetts


Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals will be the Master of Ceremonies (Emcee).

Agenda will follow

Online registration is available at the web site



Karun Rishi, President

USA-India Chamber of Commerce

Direct: 781 586-1212


Twitter: @USAIC

Read Full Post »

CHI’s Combination Immunotherapy Design Models, February 20-22, 2017, Moscone North Convention Center, San Francisco, CA – part of the 24th International Molecular Medicine Tri-Conference

Reporter: Aviva Lev-Ari, PhD, RN


Cambridge Healthtech Institute’s Fifth Annual

Combination Immunotherapy Design Models

Preclinical Approaches and Biomarkers to Bring Combination Therapies to the Clinic

February 20-22, 2017 | Moscone North Convention Center | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference

Despite tremendous progress in our understanding of cancer biology, the majority of novel anticancer therapies fail in clinical trials, which indicates deficiencies in conventional translational approaches. In most cases preclinical data have overpredicted clinical efficacy in oncology. With the rise of immuno-oncology the challenge of in vivo pharmacology was enhanced by the differences in mouse and human immune systems that further damages the predictiveness of preclinical data. The phenomenon of cancer heterogeneity and subsequent drug resistance add another dimension to the preclinical cancer research warranting active work on combination cancer regimens. Better models and approaches are clearly in high and urgent demand and has been worked on by industry and academia scientists. Cambridge Healthtech Institute’s Fifth Annual Translational Models in Oncology and Immuno-Oncology conference is designed to highlight cutting edge advances in in vivo, in vitro and in silico modeling and to facilitate a discussion about effective translational approaches in cancer research.




10:30 am Conference Program Registration Open


11:50 Chairperson’s Opening Remarks

Terri McClanahan, Ph.D., Executive Director, Molecular Discovery, Biologics, Merck Research Laboratories

12:00 pm KEYNOTE PRESENTATION: Rational Development of Combination Therapies in Immuno-Oncology

Michael Kalos, M.D., CSO, Cancer Immunobiology, Eli Lilly

Treatment of patients with combinations of agents, such as CTLA4 and PD1, has provided additional benefit to patients, along with increased toxicity, highlighting the value for developing combination therapies. In this session, we will discuss preclinical and translational strategies and approaches to support the rational development of more effective combination strategies that lead to increased clinical benefit for patients.

12:30 Biomarker Development for the Era of Combination Cancer Immunotherapy

Terri McClanahan, Ph.D., Executive Director, Molecular Discovery, Biologics, Merck Research Laboratories

Keytruda® (pembrolizumab), a PD-1-specific monoclonal antibody, is approved in the U.S. for advanced melanoma, NSCLC and SCCHN, and is being studied in >30 cancers. Efforts are now underway to extend the benefit of cancer immunotherapy to more patients through the use of anti PD-1-based combination regimens. However, significant challenges remain to identify the best combinations that provide true immune synergy, and to target the right combinations to the right patients who will experience unambiguous clinical benefit. Biomarker and translational research-driven strategies can guide the future state of the field, ultimately allowing for the development of precision medicine approaches to combination cancer immunotherapy.

1:00 Session Break

1:10 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

2:10 Session Break


2:30 Chairperson’s Remarks

Christian Gerdes, Ph.D., Head, Pharmacology, Roche Pharma Research & Early Development, Roche

2:40 Immunocompetent Mouse Models as a Tool for Cancer Immunotherapy Pipeline Advancement

Christian Gerdes, Ph.D., Head, Pharmacology, Roche Pharma Research & Early Development, Roche

As immunotherapy gains more and more traction, the need for more predictive preclinical models grows as well. It is widely recognized that immunocompetent mice are used to assess the anti-tumor efficacy of cancer immunotherapies. This presentation will discuss the uses of mouse models and how they can advance drug pipelines.

3:10 Designing and Executing Cancer Immunotherapy Clinical Trials

Pamela N. Munster, M.D., Professor, Medicine, Program Leader, Development Therapeutics, Director, Early Phase Clinical Trials Program, Helen Diller Cancer Center, University of California, San Francisco

A breakdown in immune tumor surveillance plays a crucial role in the development of metastatic cancer. Targeting the programmed death receptor (PD-1) and its ligand (PD-L1) have been major breakthroughs in certain cancers such melanoma, lung and other cancers. However, many cancers, including breast cancers, appear less responsive. We are exploring the roles of tumor lymphocyte infiltration, T cell differential, epigenetic modifiers and the co-operative involvement of other immune pathways to induce responses in immune silent tumors. Translating preclinical findings into early phase clinical studies, we will describe recent advances in how to determine safety, feasibility and efficacy of integrating immunotherapy into targeted therapy and chemotherapy.

3:40 Talimogene Laherparepvec in Combination with Checkpoint Inhibitors: From Bench to Bedside

Pedro J. Beltran, Ph.D., Research Director, Oncology Research, Amgen, Inc.

Checkpoint inhibitors and viral immunotherapy with talimogene laherparepvec have shown significant therapeutic benefit in melanoma patients when used as monotherapies. As these two forms of approved immunotherapy act mostly on different parts of the immunity cycle, studying their combination pre-clinically and clinically informs their future development. We have used 3 syngeneic murine models to study the pharmacodynamic and efficacy changes driven by the combination of talimogene laherparepvec and blockade of CTLA-4 or PD-1/PD-L1. Clinical trials testing these combinations in the clinic are currently ongoing.

4:10 Presentation to be Announced


4:25 Sponsored Presentation (Opportunity Available)

4:40 Refreshment Break and Transition to Plenary Session

5:00 Plenary Keynote Session

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day


7:30 am Registration Open and Morning Coffee

8:00 Plenary Keynote Session

9:00 Refreshment Break in the Exhibit Hall with Poster Viewing


10:05 Chairperson’s Remarks

Gavin Thurston, Vice President, Oncology and Angiogenesis Research, Regeneron Pharmaceuticals

10:15 Mouse Models to Test Human Cancer Immuno-Therapeutics

Gavin Thurston, Vice President, Oncology and Angiogenesis Research, Regeneron Pharmaceuticals

Preclinical in vivo tumor models are essential to test anti-tumor activity and side-effect profiles of novel immunotherapeutics. However, antibody-based therapies often do not cross-react with the corresponding murine targets, making such tests difficult. We have utilized Regeneron’s capabilities in murine genetic engineering to develop several approaches of combining functional immune cells with preclinical tumor models. We have used these approaches for preclinical testing of both checkpoint inhibiting antibodies and T cell-engaging bispecific antibodies.

10:45 Characterization of Molecular and Cellular Properties of Murine Syngeneic Models to Aid Model Selection and Biomarker Discovery for Immune-Oncology Programs

Wenyan Zhong, Ph.D., Senior Principal Scientist, Oncology R&D Group, Pfizer

Preclinical in vivo models for most immuno-oncology (IO) programs require the use of immunocompetent mice bearing syngeneic tumors. To facilitate model selection for use in preclinical efficacy studies, we characterized a panel of mouse tumor cell lines and syngeneic tumor tissues. In this talk, we will discuss molecular and cellular properties of these models.

11:15 Case Study: Blockade of Phosphatidylserine-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies

Michael Gray, Ph.D., Senior Research Scientist, Peregrine Pharmaceuticals

Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity of checkpoint antibodies in preclinical tumor models.

MIBioresearch11:45 Methods and Models for Preclinical Immuno-Oncology

Dylan Daniel, Ph.D., Director, Scientific Development, MI Bioresearch

MI Bioresearch has characterized an array of syngeneic immuno-oncology models to support in vivo pharmacology drug discovery. Our characterization includes comprehensive lymphoid and myeloid flow cytometry immune profiling, and model responses to checkpoint inhibitors and focal beam radiotherapy combinations.

12:00 pm Exemplar_GeneticsGenetically Engineered Miniswine Models of Cancer

John Swart, Ph.D., President, Exemplar Genetics

Current preclinical models of cancer fail to accurately recapitulate human disease and do not effectively translated to the clinic. Recently, Exemplar Genetics has developed a genetically engineered miniature swine model that contains a conditional KRAS mutation on the background of TP53-targeted pigs, the ExeGen® TP53+/R167H& KRAS+/G12D miniswine model. This model should allow for the inducement of human-like tumors in a tissue specific manner. Initial characterization of induced tumors demonstrates the transformative nature of this model.

12:30 Session Break

 Mitra Biotech12:35 Luncheon Presentation to be Announced

1:25 Refreshment Break in the Exhibit Hall with Poster Viewing


2:00 Chairperson’s Remarks

Lawrence B. Schook, Ph.D., Gutsgell Professor, Animal Sciences and Radiology, University of Illinois

2:10 Collaboration for Translation: Academic-Industry Partnerships to Explore Novel Opportunities in the Area of Immuno-Oncology

Joseph Dal Porto, Ph.D., Director, Pfizer Center for Therapeutic Innovation

The Center for Therapeutic Innovation (CTI) -San Francisco is a direct partnership between Pfizer and leading academic institutions, including UC San Francisco, UC San Diego, Stanford University and others, to establish open collaborations designed to rapidly identify targets and develop therapeutic NMEs. The long-term goal is to substantially reduce the time required to translate promising bio-medical research into new medications and therapies. Most recently, CTI has joined with academic oncology and immunology researchers to understand the translatability of emerging targets in the Immuno-Oncology therapeutic arena.

2:40 An Example of a Collaboration between Industry and Academia for Testing Combination Therapies in Preclinical Patient-Derived Xenograft Models of Glioblastoma

Anderson Clark, Ph.D., Director, Translational in vivo Pharmacology, Oncology, EMD Serono Research & Development Institute

John De Groot, Associate Professor, Chair Ad Interim, Neuro-Oncology, The University of Texas MD Anderson Cancer Center

The use of patient-derived xenograft (PDX) models of cancer has increased over the past decade, both in industry and academia, providing preclinical data to support both drug development and basic oncology research.

3:20 The Oncopig Cancer Model (OCM): A Platform for Transitional, Translational and Transformative Advances in Cancer Research

Lawrence B. Schook, Ph.D., Gutsgell Professor, Animal Sciences and Radiology,

University of Illinois

Mammalian models are integral components of basic, translational, and clinical cancer research. Recently, there have been advances in creating large animal transitional porcine cancer models, for use in preclinical and translational research studies with transformational impact for human clinical trials. Pigs, due to their anatomy, physiology, metabolism, and genetics, provide an ideal investigational transitional platform for human clinical trials and offer a critical pathway to narrow gaps in cancer therapy.

3:40 Presentation to be Announced


4:10 Hollywood Oscar Dessert Reception in the Exhibit Hall with Poster Viewing

5:00 Breakout Discussions in the Exhibit Hall

These interactive discussion groups are open to all attendees, speakers, sponsors, & exhibitors. Participants choose a specific breakout discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion. Pre-registration to sign up for one of the topics will occur a week or two prior to the Event via the App.

Humanized Mouse Models

Gavin Thurston, Vice President, Oncology and Angiogenesis Research, Regeneron Pharmaceuticals

  • Appropriate applications of humanized mouse models in immuno-oncology
  • Limitations of current models
  • Areas of future development

Next Generation Cellular Models

Scott Martin, Senior Scientific Manager, Group Lead, Functional Genomics, Discovery Oncology, Genetech Inc.

  • Cancer cell line profiling
  • Large-scale genomic and drug response screening
  • Future directions

Biomarkers for Cancer Combination Design

Jianda Yuan, M.D., Ph.D., Director, Translational Immuno-Oncology Research, Early Clinical Oncology Development, Merck & Co., Inc.

  • Validation of biomarkers before use in clinical care
  • Using prognostic and predictive biomarkers for enrichment and stratification factors in drug development
  • Challenges and Implementation of biomarkers into clinical practice

6:00 Close of Day


7:00 am Registration Open

7:00 Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Session

10:00 Refreshment Break and Poster Competition Winner Announced in the Exhibit Hall


10:50 Chairperson’s Remarks

Jianda Yuan, M.D., Ph.D., Director, Translational Immuno-Oncology Research, Early Clinical Oncology Development, Merck & Co., Inc.

11:00 Next Generation Biomarkers for the Era of Combination Cancer Immunotherapy

Jianda Yuan, M.D., Ph.D., Director, Translational Immuno-Oncology Research, Early Clinical Oncology Development, Merck & Co., Inc.

Sarah Javaid, Ph.D., Senior Scientist, Discovery Pharmacogenomics, Genetics and Pharmacogenomics, Merck & Co., Inc.

Combination approaches are the keys to improving clinical response. From preclinical immune-oncology mouse models to patients enrolled on clinical trials, novel high throughput technologies enable us to understand the mechanisms underlying the complex interactions between the immune system and cancer, identify predictive biomarkers for the patients who will most likely benefit from current immunotherapies, avoid immune-related adverse events and guide the future combination cancer immunotherapy.

11:30 High-Content Molecular Profiling in Preclinical Immuno-Oncology Research

Ruslan Novosiadly, Senior Research Advisor, Cancer Immunobiology, Biomarkers, Eli Lilly

Recent clinical data have revealed the remarkable potential for T cell modulating agents to induce potent and durable responses in a subset of cancer patients. In this presentation, we discuss molecular approaches, platforms and strategies that enable a broader interrogation of the activity of agents that modulate the activity of tumor-specific T cells as well as examples of data sets generated in preclinical studies that have provided important insights into the biological activity of T cell therapies and support further rational development of this exciting treatment modality.

12:00 pm Utility of Quantifying Circulating Lymphocyte Populations as Pharmacodynamic Biomarkers in Trials of Immune Oncology Therapeutics

Nathan Standifer, Ph.D., Scientist II, Clinical Pharmacology and DMPK, MedImmune

Immune oncology (IO) therapeutics are directed at inducing immune responses against tumor cells. Intrinsic to this mechanism of action is the activation of circulating immune cells, which can be most effectively monitored using flow cytometry-based assays. In this presentation, aspects of assay development, validation, implementation and analysis of clinical flow cytometry datasets will be discussed. Results from clinical trials of IO as single agents or in combination with other IO will be shown and strategies for interpretation and post-hoc analyses will be detailed.

12:30 Session Break

Cellecta 12:40 Luncheon Presentation to be Announced


1:10 Refreshment Break in the Exhibit Hall and Last Chance for Poster Viewing


1:50 Chairperson’s Remarks

Scott Martin, Senior Scientific Manager, Group Lead, Functional Genomics, Discovery Oncology, Genetech

2:00 Understanding and Predicting Cellular Response through Chemical and Functional Genomic Profiling of Well-Characterized Cancer Cell Lines

Scott Martin, Senior Scientific Manager, Group Lead, Functional Genomics, Discovery Oncology, Genetech

Determining relationships between genomic features and drug sensitivity is central to the concept of personalized medicine and indication selection. Many studies have highlighted the value of integrating omics data with drug activity across cell lines to identify predictors of response. Here we extend upon these studies with numerous chemical and genetic perturbations to explore such relationships. Data reveals both known and novel correlations, and was also used to explore best experimental and computational practices.

2:30 Beyond Genomics: Identifying Treatment Options for Refractory Cancer Patients Using Real Time Functional Assays and FDA Approved Drug Combinations

Matthew De Silva, CEO, Founder, Notable Labs

Refractory cancer patients often have resistant disease that does not respond to single agent therapy. Combination strategies are promising, but patient heterogeneity makes clinical trial design difficult. Next generation functional phenotypic assays using a patient’s cancer cells can identify potentially synergistic treatments in a matter of days, but the combinatorial space is often larger than the available cells. In silico models that employ ‘omic data from a patient can prioritize which combinations to test ex vivo. If the agent(s) of choice are approved, physicians can then prescribe them

3:00 Generation of ex vivo Tumor Models from PDX Tumors as a Platform for Clinically Relevant Anticancer Drug Discovery

Geoffrey A. Bartholomeusz, Ph.D., Associate Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Monolayer cell cultures platforms inadequately represent the complex tumor microenvironment and drugs identified by these systems have failed when translated into the clinics. Clinically relevant PDX systems are both costly and time consuming. We have developed a clinically relevant ex vivo tumor tissue system derived from a PDX tumor, and preliminary data confirms its potential to serve as a platform for clinically relevant drug discovery in a time and cost effective manner.

3:30 Session Break


3:40 Chairperson’s Remarks

Monte Winslow, Ph.D., Assistant Professor, Genetics, Stanford University

3:45 Cancer Modeling with in vivo CRISPR/Cas9 Genome Editing

Monte Winslow, Ph.D., Assistant Professor, Genetics, Stanford University

Conventional genetically engineered mouse models of human cancer have been instrumental in our understanding of all aspects of cancer development. However, these models are much too labor-intensive, expensive, and slow to perform the extensive molecular analyses needed to adequately comprehend this disease. I will discuss our ongoing work to employ CRISPR/Cas9-mediated genome editing to generate cancer models and illuminate gene function during cancer progression within the natural in vivo setting.

4:15 Tailored Pre-Clinical Models with CRISPR-Based Genome Editing

Lukas Edward Dow, Assistant Professor, Medicine, Weill Cornell Medicine

CRISPR/Cas9 genome editing has changed the way we design and execute in vivo experiments. We are using CRISPR-based genome editing in stem cells and in adult mice to generate tailored pre-clinical models. This allows both a deeper understanding of the genetic underpinnings of cancer progression and provides a platform to interrogate new therapeutic strategies in specific genetic contexts, which is key for realizing the potential of personalized medicine.

4:45 The Human Cancer Model Initiative

Louis M. Staudt, M.D., Ph.D., Director, Center for Cancer Genomics, Co-Chief, Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health

The Human Cancer Model Initiative (HCMI) aims to generate 1000 new cancer cell lines directly from patient biopsy material using a variety of technologies, including organoids and conditionally reprogrammed cells. Each cell line will be genomically characterized and clinical diagnostic and therapeutic data will be gathered from the participating patients. The new cell lines and their associated data will be made available to the research community to promote a deeper understanding of cancer and its response or resistance to therapy.

5:15 Close of Conference Program



From: Marina Filshtinsky <pete@healthtech.com>

Date: Wednesday, December 14, 2016 at 10:00 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Combination Immunotherapy Design Models

Read Full Post »

Super RECORD of REAL TIME Coverage of Biotech and Medicine Conferences by LPBI Group in 2016

Curator: Aviva Lev-Ari, PhD, RN


2013 to Present List of BioTech Conferences covered in Real Time


2016 List of BioTech Conferences covered in Real Time


  • The 12th Annual Personalized Medicine Conference, NOVEMBER 15 – 17, 2016, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston



  • The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

Agenda @Biotech Week Boston: WHERE THE HEART, TECHNOLOGY AND BUSINESS OF SCIENCE CONVERGE, Conference: October 4 – 7, 2016 | Exhibition: October 5-7, 2016 Boston Convention and Exhibition Center


  • CHI’s 14th Annual Discovery on Target: Preliminary Agenda Available and Exclusive Discount to attend Boston’s Discovery on Target (September 19-22, 2016)



  • Understanding CRISPR: Mechanisms and Applications: CHI, September 19-22, 2016, Westin Boston Waterfront, Boston

Preliminary Agenda Available and Exclusive Discount to attend Understanding CRISPR: Mechanisms to Applications Symposium in Boston (September 19, 2016)



Announcement from LPBI Group: key code LPBI16 for Exclusive Discount to attend Boston’s Discovery on Target (September 19-22, 2016, CRISPR: Mechanisms to Applications on 9/19/2016)



  • Oncolytic Virus Immunotherapy Unlocking Oncolytic Virotherapies: From Science to Commercialization CHI’S 4TH ANNUAL IMMUNO-ONCOLOGY SUMMIT – AUGUST 29-30, 2016 | Marriott Long Wharf Hotel – Boston, MA



  • CHI’S 4THANNUAL IMMUNO-ONCOLOGY SUMMIT – Personalized Immunotherapy | The Immuno-Oncology Summit Personalized Oncology in the Genomic Era: Expanding the Druggable Space, August 30-31, 2016 | Marriott Long Wharf Hotel – Boston, MA



  • 10th US-India BioPharma & Healthcare Summit, Thursday, June 2, 2016, Marriott Cambridge, MA



  • 2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston



  • 2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA



Press Coverage is a Service that we offer to Biotech and Medicine, Scientific and Business Conference Organizers.


Channels for e-Marketing of Biotech Conferences



  • Our Journal has +1,115,681 eReaders on 12/14/2016, for All Time



  • Aviva’s – +6000 BIOTECH followers on LinkedIn



  • LPBI Group’s FaceBook Page



  • LPBI Group’s Twitter Account



  • Aviva Manages three Groups on LinkedIn


a.       Cardiovascular Biotech & Pharma UK & US Networking Group

906 members



b.       Leaders in Pharmaceutical Business Intelligence

336 members



c.         Innovation in Israel

172 members



  • LPBI Group’s Company’s Page on LinedIn


Deliverables for 2016 Biotech Conference Coverage



Read Full Post »

2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston


Reporter: Aviva Lev-Ari, PhD, RN



Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover the event in REAL TIME

Aviva Lev-Ari, PhD, RN will be streaming live from the floor of the Westin Hotel in Boston on May 1-3, 2017




Biggest Voices in Cardiovascular Care

2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston

Monday, May 1, 2017

7:00 am – 8:00 am
8:00 am – 11:30 am
First Look: The Next Wave of Cardiology Breakthroughs

Harvard Medical School investigators describe their most promising work in rapid fire presentations highlighting commercial opportunities in cardiovascular and cardiometabolic care. Twenty rising stars from Brigham and Women’s Hospital and Massachusetts General Hospital will present in 10-minute sessions.

11:45 am – 1:15 pm
Concurrent Discovery Cafés Breakout Sessions: Sharing Perspectives

Top Cardiology faculty from Brigham and Women’s Hospital and Massachusetts General Hospital address compelling topics in clinical research and implementation of care.

Topics to be covered include:

  • Cardiac Replacement Therapy: The Next Ten Years
  • Heart Failure: Back in The Game through New Pathways
  • Payment Models: Provider’s Perspective
  • Microbiome: Implications for Cardiovascular and Metabolic Disease
  • Molecular Imaging: New Biological Endpoints – Function Over Structure
  • Technology: Enhancing Translational Medicine


1:15 pm – 1:30 pm
1:30 pm – 1:40 pm
Opening Remarks
Introduction by: Anne Klibanski, MD
  • Chief Academic Officer, Partners HealthCare
  • Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School
  • CEO, Partners HealthCare
1:40 pm – 2:15 pm
Reinventing Cardiac Care

Two renowned clinical leaders provide an overview of the medical and economic challenges that cardiovascular and cardiometabolic disorders present.

They will highlight strategic direction in cardiac research and clinical care at Partners, and address how recent trends in investment, regulation, and policy may be dovetailed with efforts at Partners.

The experts also spotlight for attendees the various therapies, diagnostics, devices, and critical issues that will be discussed throughout the upcoming 2.5 days of the World Medical Innovation Forum.

  • CEO, Southern Cross Biotech Consulting
  • Chief of Cardiovascular Medicinem Brigham and Women’s Hospital
  • Associate Professor of Medicine, Harvard Medical School
  • Chief, Cardiology Division, Massachusetts General Hospital
  • Professor of Medicine, Harvard Medical School
2:15 pm – 3:05 pm
CEO Roundtable: Today’s Learning, Tomorrow’s Opportunities

Discussion on contribution of technology innovation to the treatment of cardiovascular disease reflecting on lessons and how they shape investment decisions.

Moderator: Benjamin Pless
  • Executive in Residence, Partners HealthCare Innovation
  • EVP Medical Affairs and CMO, UnitedHealth Group
  • CEO, Abiomed
  • CEO, Edwards Lifesciences
  • CEO, Bard
3:05 pm – 3:55 pm
Tackling the AFib Epidemic

Evolving trends in diagnosis, prevention, and treatment of atrial fibrillation. Factors that will influence patient care over the next 5 years are considered, including risk stratification, procedure and technology options, and potential implications of CMS policies, such as bundling.


  • Associate Chief, Cardiology Division, Massachusetts General Hospital Heart Center
  • Professor of Medicine, Harvard Medical School
  • Director, Cardiac Arrhythmia Service, Massachusetts General Hospital
  • Associate Professor, Harvard Medical School
  • VP, GM, AF Solutions, Medtronic
  • President, Cardiovascular and Neuromodulation, Abbott
  • VP US Medical Affairs, CVMD TA, AstraZeneca
3:55 pm – 4:45 pm
Heart Failure’s Therapeutic Mandate

One million patients are hospitalized annually for HF—80% of total US cost of HF management. After discharge from HF hospitalization, 24% are rehospitalized within 30 days, greater than 50% within 6 months. Perspective on disease management, addressing the issues of hospital readmission and optimizing therapies.


  • VP and Medical Director, Abbott
  • CEO, MyoKardia
  • SVP, CMO, Global Health Policy, Rhythm Management, Boston Scientific
4:45 pm – 5:50 pm

PAD is the most challenging atherosclerotic syndrome, largely due to the technological challenges of managing peripheral artery disease through minimally invasive strategies. Top physician, governmental, and industry leaders in the field discuss the potential for new breakthroughs including novel implantable devices, pharmacologic approaches, and reductions in associated cardiovascular morbidity and mortality.

The panel will also discuss, Below The Knee: The Persisting Unmet Need


Moderator: Michael Jaff, DO
  • President, Newton-Wellesley Hospital, Partners Healthcare
  • Professor of Medicine, Harvard Medical School
  • Director, Coverage and Analysis Group, CMS
  • Chief, Peripheral Interventional Devices Branch, Food and Drug Administration
  • CMO, Cardinal Health
  • Co-Director, Endovascular Surgery, Brigham and Women’s Hospital
  • Assistant Professor, Harvard Medical School
  • SVP and President, Peripheral Interventions, Boston Scientific
6:00 pm – 6:45 pm

Tuesday, May 2, 2017

7:00 am – 7:45 am
7:00 am – 7:45 am
FOCUS SESSION: Japan Today: Advancing Cardiometabolic Therapies

Discussion on unique aspects of cardiometabolic market in Japan, its projected trend over the next 5 years and explore transformative models of open innovation to accelerate development of new therapeutic options.

  • Yoshiro Miwa Associate Chair and Founding Director, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women’s Hospital
7:00 am – 7:10 am
  • Chief Innovation Officer, Partners HealthCare
8:00 am – 8:50 am
Pricing to Enable Affordability and Innovation

Balancing acceptable answers to high and escalating drug prices in the United States while making strides in medical innovation. Leaders in innovation, policy, care delivery, academia, and insurance discuss potential collaborative solutions.


Moderator: Peter Slavin, MD
  • President, Massachusetts General Hospital
  • CEO, Cardinal Health
  • CEO, Boehringer Ingelheim USA
8:50 am – 9:40 am
CLINICAL HIGHLIGHT: Emerging Devices for Complex Structural Heart Disease

Evolution of mitral disease management, current practice and impact of new technologies on both repair and replacement, implications of a heterogeneous patient population, triage, timing of intervention.

  • CVP, Advanced Technology, CSO, Edwards Lifesciences
  • SVP and President, Coronary & Structural Heart, Medtronic
9:40 am – 10:10 am
1:1 Fireside Chat: John Lechleiter, Chairman, Eli Lilly
Moderator: Susan Dentzer
  • CEO, Network for Excellence in Health Innovation
  • Chairman, Eli Lilly and Company
10:10 am – 10:25 am
10:25 am – 11:15 am
Personal Monitoring for Disease Management

Considering the evolving trends in viability and utilization and the opportunities wearables may present for real-world clinical decision making.


Moderator: Joe Kvedar, MD
  • VP, Connected Health, Partners HealthCare
  • Associate Professor of Dermatology, Harvard Medical School
  • CEO, GE Healthcare
  • CEO, Philips
  • CEO, Siemens Healthcare
  • CEO, Zoll Medical
11:15 am – 11:45 am
1:1 Fireside Chat: Omar Ishrak, CEO, Medtronic
Moderator: Paul LaViolette
  • Managing Partner & COO, SV Life Sciences Advisers
  • CEO, Medtronic
12:00 pm – 12:30 pm
12:15 pm – 12:30 pm
1:00 pm – 1:10 pm
1:10 pm – 2:00 pm
Global Clinical Trials: Next Generation Design and Scalability

Cardiovascular trials currently account for 10 percent of all clinical trial participants. Discussion on design and implementation of clinical studies globally, considering strategies for patient access, regulatory implications, cost containment and management of relationships with global service providers.


  • Chairman, TIMI Study Group, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, Brigham and Women’s Hospital
  • VP, Cardiovascular & Metabolic Disease Head, Global Medicines Development, AstraZeneca
  • VP Cardiovascular Medicine, Covance
  • Vice President, Global Development, Amgen
2:00 pm – 2:50 pm
Precision Cardiovascular Medicine: What is Different This Time

Explore how precision medicine is changing the face of cardiovascular medicine specifically. The session will examine the impact of combined phenotypic and genotypic characterization on optimizing response to therapeutics, trial design, improving outcomes, and redefining reimbursement.

  • CEO, GE Ventures & healthymagination
2:50 pm – 3:40 pm
CV Investing in the Next Decade

View on investing landscape, opportunities in the CV/metabolic marketplace, the drugs, devices and diagnostics currently in pipelines and notable positive trends.

  • Partner, Atlas Venture
  • VP, Venture, Partners HealthCare
  • Managing General Partner, Frazier Healthcare Partners
3:40 pm – 4:30 pm
CLINICAL HIGHLIGHT: Optimizing Care for the 51%: New Market Opportunities

Introduction: Cathy Minehan, Chair, MGH Corporation

Address implications of gender as a key biological factor for personalized medicine. Stroke is likely to be the first cardiovascular event, tied to AF and secondarily to hypertension. Opportunities for medication utilization and optimization in context of, manifestation of disease and understanding the biology, complications, strategies to collect relevant clinical evidence, and treatment response.

  • CEO, American Heart Association
  • Medical Director, Boston Scientific
4:30 pm – 5:20 pm
Disruptive Therapeutic Platforms: New Tools, New Outcomes

Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases including heart failure. These emerging drugs could be considered in context of genomic/germ line screening, family history and epigenetics.

Moderator: Tony Coles, MD
  • CEO, Yumanity Therapeutics
  • Founder, AnGes
5:20 pm – 6:00 pm

Wednesday, May 3, 2017

7:30 am – 7:55 am
1:1 Fireside Chat: Robert Califf, Commissioner (former), Food and Drug Administration
  • Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital
  • Hersey Professor of the Theory and Practice of Medicine, Soma Weiss, MD Distinguished Chair in Medicine, Harvard Medical School
  • Commissioner (former), Food and Drug Administration
7:55 am – 8:45 am
Innovation in Translational Trials

CV/metabolic disorders comprise aggregates of many niche diseases that may be targeted with therapies against specific molecular alterations, yet the final potential markets are much larger. This model creates challenges for both drug development and patient care with implications for initial indication selection and design and execution of clinical trials – from first-in-human through post marketing studies.


  • SVP, Global Head of Regenerative Medicine Unit, Head of Scientific Affairs, Japan, Takeda
  • CEO, Mirna Therapeutics
  • SVP, R&D Pipeline, GlaxoSmithKline
  • CMO, Verily
  • Senior Vice President & CSO, PAREXEL International
9:15 am – 10:05 am
New Targets in Coronary Artery Disease

Cardiovascular trials have a proud history of providing some of the most robust data in evidence-based medicine. However the growing size and complexity of these trials imperils their future. This panel will discuss the design and implementation of clinical studies globally, considering strategies for patient access, leveraging electronic health records and mobile device data, personalized medicine, regulatory implications, cost containment and management of relationships with global service providers.

  • Director, Center for Human Genetic Research, Massachusetts General Hospital
  • Associate Professor of Medicine, Harvard Medical School
  • VP Research, Cardiometabolic Disorders Therapeutic Area Head, Site Head Amgen San Francisco, Amgen
  • Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital
  • Eugene Braunwald Professor of Medicine, Harvard Medical School
10:05 am – 10:25 am
10:25 am – 10:55 am
1:1 Fireside Chat: Gary Gibbons, NHLBI
Moderator: Betsy Nabel, MD
  • President, Brigham and Women’s Hospital
  • Director, NHLBI
10:55 am – 11:45 am
The Skinny on Fat: Therapeutic Opportunities

Explore the evolving role of adipose tissue as an active endocrine organ and discuss the possibilities to discover novel signaling pathways relevant to cardiovascular health and viable druggable targets.

  • SVP and US Medical Leader, Eli Lilly and Company
  • SVP and CSO, CVMET, Pfizer
  • CEO, Zafgen
  • VP, Therapy Area, Cardiovascular & Metabolism, AstraZeneca
11:45 am – 12:45 pm
Disruptive Dozen: 12 Technologies that will reinvent Cardiovascular Care
  • Chief of Cardiovascular Medicinem Brigham and Women’s Hospital
  • Associate Professor of Medicine, Harvard Medical School


Listen to some of the top CEOs in the cardiovascular industry discuss their latest innovations.

Forum keynoters will include the CEOs of Eli Lilly, Boston Scientific, Medtronic, Boehringer Ingelheim, Cardinal Health, Edwards Life Sciences, Abiomed, Bard, American Heart Association, GE Healthcare, Siemens Healthcare, the FDA Commissioner and dozens of top investors, emerging company CEOs, and senior Harvard faculty. Be part of the new urgency to redefine cardiovascular and cardiometabolic care – the largest market in healthcare – through new therapies, digital diagnostics, ‘omics, platforms and engagement.

To join fellow decision makers at the World Medical Innovation Forum, please follow the link to register: worldmedicalinnovation.org



John Lechleiter, PhD

CEO, Eli Lilly and Company

George Barrett

CEO, Cardinal Health

Robert Califf, MD

Commissioner, Food and Drug Administration

Michael Mussallem

CEO, Edwards LifeSciences

Tony Coles, MD

CEO, Yumanity Therapeutics

Nancy Brown

CEO, American Heart Association

Frans van Houten

CEO, Philips

Bernd Montag, PhD

CEO, Siemens Healthcare

Michael Minogue

CEO, Abiomed

Tamara Syrek Jensen

Director, Coverage and Analysis Group, CMS

Betsy Nabel, MD

President, Brigham and Women’s Hospital

Richard Migliori, MD

EVP Medical Affairs and CMO, UnitedHealth Group

Jean-François Formela, MD

Partner, Atlas Venture

Patrick Vallance, MD, PhD

R&D President, GlaxoSmithKline

Tassos Gianakakos

CEO, MyoKardia


Michael Mahoney

CEO, Boston Scientific

Omar Ishrak, PhD

CEO, Medtronic

John Flannery

CEO, GE Healthcare

Timothy Ring

CEO, Bard

Jessica Mega, MD

CMO, Verily

Gary Gibbons, MD

Director, NHLBI

Sue Siegel

CEO, GE Ventures & healthymagination

Jonathan Rennert

CEO, ZOLL Medical

Paul Lammers, MD

CEO, Mirna Therapeutics

André-Michel Ballester, PhD

CEO, LivaNova

Paul Fonteyne

CEO, Boehringer Ingelheim USA

Paul LaViolette

Managing Partner and COO, SV Life Sciences Advisers

Ora Pescovitz, MD

SVP and US Medical Leader, Eli Lilly and Company

Jeff Mirviss

SVP and President, Peripheral Interventions, Boston Scientific

Fouzia Laghrissi-Thode, MD

VP, Therapy Area, Cardiovascular & Metabolism, AstraZeneca




  • New Targets in Coronary Artery Disease
  • PAD: Improving Outcomes

Clinical Evidence & Care Pathway

  • Gender and Cardiovascular Disease
  • Global Clinical Trials: Next Generation Design and Scalability
  • Innovations in Cardiac Delivery
  • Innovation in Translational Trials

Innovation and Policy

  • Cardiovascular Innovation: Triumphs, Challenges, Opportunities
  • Pricing to Enable Affordability and Innovation
  • Regulatory Priorities: FDA Commissioner (invited)
  • Technology, Populations and Disease: CV Investing in the Next Decade


Heart Failure

  • Heart Failure: Back in the Game Through New Pathways

Metabolic Syndrome

  • Cardioprotective Effects of Metabolic Drugs
  • The Skinny on Fat: Therapeutic Opportunities


  • Disruptive Therapeutic Platforms: From Nucleic Acid to Proteins
  • Personal Monitoring for Disease Management
  • Precision Cardiovascular Medicine: What is Different This Time?

Rhythm Disorders

  • A Cure for AFib: Drugs, Ablation or Lifestyle?

Structural Heart

  • Emerging Devices for Complex Structural Heart Disease




The 2017 World Medical Innovation Forum, May 1-3, 2017, will be held at the Westin Copley Place in Boston, Massachusetts.

Register Today.

Early bird discounts apply.

Sign up before December 31.


For more information contact:

Chris Coburn

Chief Innovation Officer

Partners HealthCare




Partners HealthCare Innovation

Partners HealthCare

Add to Calendar

Contact Us



From: Partners HealthCare Innovation <innovations@partners.org>

Date: Wednesday, December 14, 2016 at 9:47 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Cardiovascular’s next chapter of innovation begins now.

Read Full Post »

Preliminary Agenda Available: World Preclinical Congress 2017 (June 12-16 in Boston, MA)

Reporter: Aviva Lev-Ari, PhD, RN



The preliminary agenda is now available for CHI’s 16th Annual World Preclinical Congress taking place June 12 – 16, 2017 at The Westin Copley Place in Boston, MA.

In recent years, the World Preclinical Congress (WPC) has turned into a key networking event for those involved in preclinical research. It features conferences, training seminars and short courses that cover the very latest in preclinical strategies and technologies, to enable better and faster decisions in drug discovery. WPC attracts a diverse, global audience, which include experts, as well as people who are new and eager to contribute to the field.

Now in its 16th year the event will continue to highlight ways to improve accuracy and efficiency in preclinical research, while bringing together the people and technologies to make it happen. Spanning five days, the event attracts 1,000+ attendees including chemists, biologists, pharmacologists, toxicologists, screening and formulation experts.

This year’s event is comprised of 14 conference tracks, 5 Symposia, 10 short courses*, interactive breakout discussion groups, an exhibit hall featuring more than 80 technology and service companies, Student Fellowship Program and dedicated poster viewing and networking sessions. The 16th Annual World Preclinical Congress event assembles an impressive group of distinguished speakers who look forward to sharing their knowledge, best practices, and expertise with all attendees.

Don’t miss your opportunity to network with 1,000+ of your peers at this year’s event. Special early registration savings are currently available.

We look forward to seeing you this June in Boston, Massachusetts.


Bethany Gray

Director of Product Marketing

Cambridge Healthtech Institute


From: Bethany Gray <bethanyg@worldpreclinicalcongress.com>

Date: Monday, December 5, 2016 at 2:15 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Preliminary Agenda Available: World Preclinical Congress 2017 (June 12-16 in Boston, MA)

Read Full Post »

Older Posts »